TY - JOUR
T1 - Biological therapies for the treatment of Behçet's disease-related uveitis beyond TNF-alpha blockade: a narrative review
AU - Sota, Jurgen
AU - Rigante, Donato
AU - Lopalco, Giuseppe
AU - Frediani, Bruno
AU - Franceschini, Rossella
AU - Galeazzi, Mauro
AU - Iannone, Florenzo
AU - Tosi, Gian Marco
AU - Fabiani, Claudia
AU - Cantarini, Luca
PY - 2018
Y1 - 2018
N2 - Intraocular inflammation is one of the more relevant complications of Behçet's disease (BD), which tends to respond poorly to different medications. The ocular histopathologic changes are basically identical to those occurring in other organs and consist in a necrotizing leukocytoclastic obliterative vasculitis, which is probably immune complex-mediated and affects both arteries and veins of all sizes. There are growing evidences showing the potential role of biologic agents other than anti-tumor necrosis factor (TNF)-α agents in the management of ocular BD, which have been collected in this review, including interleukin-1 and interleukin-6 blockade, secukinumab, ustekinumab, daclizumab, rituximab, and alemtuzumab. Further large studies are needed to fully elucidate and establish the clinical efficacy of these different tools in the refractory ocular manifestations of BD.
AB - Intraocular inflammation is one of the more relevant complications of Behçet's disease (BD), which tends to respond poorly to different medications. The ocular histopathologic changes are basically identical to those occurring in other organs and consist in a necrotizing leukocytoclastic obliterative vasculitis, which is probably immune complex-mediated and affects both arteries and veins of all sizes. There are growing evidences showing the potential role of biologic agents other than anti-tumor necrosis factor (TNF)-α agents in the management of ocular BD, which have been collected in this review, including interleukin-1 and interleukin-6 blockade, secukinumab, ustekinumab, daclizumab, rituximab, and alemtuzumab. Further large studies are needed to fully elucidate and establish the clinical efficacy of these different tools in the refractory ocular manifestations of BD.
KW - Behçet's disease
KW - Uveitis
KW - Behçet's disease
KW - Uveitis
UR - http://hdl.handle.net/10807/104569
U2 - 10.1007/s00296-017-3775-5
DO - 10.1007/s00296-017-3775-5
M3 - Article
SN - 0172-8172
VL - 38
SP - 25
EP - 35
JO - Rheumatology International
JF - Rheumatology International
ER -